Clinical Trial

A Study to Evaluate the Safety, Tolerability, and Efficacy of TML-6 in Participants With Early Alzheimer's Disease

Name: A Study to Evaluate the Safety, Tolerability, and Efficacy of TML-6 in Participants With Early Alzheimer's Disease — clinical trial record (NCT07612150)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

The primary purpose of the study is to assess if treatment with TML-6 for 52 weeks will be effective in slowing, stopping, or improving cognitive and functional decline in participants with early Alzheimer's Disease (AD) as compared to participants receiving placebo.

Trial Details

NCT Number	NCT07612150
Lead Sponsor	Merry Life Biomedical Co., Ltd.
Conditions	Alzheimer Disease
Enrollment	210 participants
Start Date	2026-08-01
Primary Completion	2028-04-30 (estimated)
Study Completion	2028-07-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-28